Publications

The publication of research results is a fundamental requirement for improving treatment concepts across the board. iOMEDICO supports the international guidelines on transparency and publication of medical research results.

We regularly present our data at national and international conferences. Our publications appear in scientifically renowned, international journals. Authors are principal investigators, investigators with a high number of participating patients, and iOMEDICO scientists.

TITEL
STUDIE
JAHR
Durvalumab Consolidation After Definitive Chemoradiotherapy in Patients with Unresectable Stage III Non-Small Cell Lung Cancer: A Real-World Cohort Analysis from the German Prospective, Observational CRISP Registry (AIO-TRK-0315)

Stuschke M, Thomas M, Gröschel A, Sebastian M, Reck M, Hoffknecht P, Grah C, Spring L, Jänicke M, Lennartz C, Ludwig P, Groth A, Sadjadian P, Christopoulos P, Christoph DC, Griesinger F, Passlick B, Eberhardt WEE, on behalf of the CRISP Registry Group.

Cancers. 2026; 18(14):2316.

Abstract

Indikation: Lung Cancer, Lungenkarzinom / Veranstaltung: - / Journal: Cancers
CRISP
2026
Lenalidomide plus dexamethasone as first-line therapy in transplant-ineligible patients with multiple myeloma: Final results of the prospective, non-interventional study FIRST-NIS and comparison with the FIRST pivotal phase III clinical trial.

Nückel H, Behlendorf T, Schulz H, Schulze M, Schardt C, Medinger T, Koenigsmann M, Dechow T, Indorf M, Bürkle D, Engelbertz V1, Rauh J11, Schmidt B1, Sauer A1, Vannier C, Potthoff K.

Cancer Medicine 15, no. 4 (2026): e71758

Abstract

Indikation: Multiple Myeloma, Multiples Myelom / Veranstaltung: - / Journal: Cancer Medicine
FIRST-NIS
2026
Unmet need for patients with metastatic triple-negative breast cancer initiating first-line treatment: data from the prospective German tumor registry OPAL. ESMO Real World

Stickeler E, Decker T, Zahn MO, Thill M, Zaiss M, Nusch A, Teutsch C, Wang M, Kuske A, Ringwald K, Kruggel L, Harbeck N, Wöckel A, Welt A, Gratzke K; OPAL registry group.
ESMO Real World Data Digit Oncol. 2026 Apr 7;12:100699.

Abstract

Indikation: Breast Cancer, Mammakarzinom / Veranstaltung: - / Journal: ESMO Real World Data and Digital Oncology
OPAL
2026
Prediction of dose reductions and impact of reduced starting doses of CDK4/6i on effectiveness in HR-positive/HER2-negative metastatic breast cancer: Real-world data from the OPAL registry.

Patrick Marschner, Kai Ringwald, Marc Thill, Mark-Oliver Zahn, Anja Welt, Arnd Nusch, Gabriele Kaltenecker, Yolanda Rodemer, Volker Hagen, Caroline Schock, Lisa Kruggel, Anja Kaiser-Osterhues, Dunja Klein, Nina Haug, Elmar Stickeler, Nadia Harbeck, Achim Wöckel, Norbert Marschner, Thomas Decker, the OPAL Registry Group

Int J Cancer. 2026;1-13. doi:10.1002/ijc.70433

Abstract

Indikation: Breast Cancer, Mammakarzinom / Veranstaltung: - / Journal: International Journal of Cancer
OPAL
2026
Treatment and outcomes of patients with HR+/HER2− early breast cancer in a real-world setting in Germany. Real-world data on HR+/HER2− EBC: a German registry analysis.

Däßler KU, Petersen V, Zahn MO, Fakhouri W, Korfel A, Emde A, Rößler T, Kruggel L, Tech S, Jänicke M, Gratzke K.

Cancer Treatment and Research Communications. Januar 2026;101122.
Abstract

Indikation: Breast Cancer, Mammakarzinom / Veranstaltung: - / Journal: Cancer Treatment and Research Communications
TMK
2026
Final results of the INFINITY precision oncology registry: non-standard targeted treatments in patients with advanced cancers in routine care. ESMO Real World Data and Digital Oncology.

L. Sellmann, D. Marschner, U.M. Martens, J. Schröder, T. Decker, M. Schuler, A. Schneeweiss, M. Reiser, M.K. Schuler, C. Vannier, M. Looß, S.M. Woerner, S. Grebhardt, P.R. Wright, S. Dille, B. Kasenda, S. Busies, K. Potthoff.

ESMO Real World Data and Digital Oncology. Volume 11, 2026, 100667, ISSN 2949-8201.

Abstract

Indikation: Präzisionsonkologie, Precision Oncology / Veranstaltung: - / Journal: ESMO Real World Data and Digital Oncology
INFINITY
2026
Institutionelle Variabilität in der Testung auf therapierelevante Treibermutationen bei Patienten mit NSCLC im Stadium IIIB/C oder IV: Real-World Daten aus dem prospektiven, multizentrischen CRISP-Register (AIO-TRK-0315)

Althoff, Friederike C., Hummel, H.-D., Kokowski, K., Elender, C., Grah, C., Jänicke, M., Fleitz, A., Zacharias, S., Groth, A., Ludwig, P., Nusch, A., Marcel, R., Pelz, H., Wiegand, J., Griesinger, F., Thomas, M., Eberhardt, W., Sebastian, M., DGHO 2025.

Oncol Res Treat 2025;48 (suppl 2):199

Poster

Indikation: Lung Cancer, Lungenkarzinom / Veranstaltung: DGHO / Journal: Oncology Research and Treatment
CRISP
2025
Real-world data on systemic treatment and biomarker testing in patients with advanced or metastatic endometrial cancer: results from the German registry platform SMARAGD

Juhasz-Böss I., Decker T., Zaiss M., Flade F., Beurer B, Jaenicke M., Winter S., Georganoudis N., Marschner N., Stickeler E., Welt A., Watermann D., Wöckel A., Gratzke K., , 2025,

International Journal of Gynecological Cancer, Volume 35, Issue 2, Supplement 1, 2025,100692, ISSN 1048-891X, https://doi.org/10.1016/j.ijgc.2024.100692.

Poster

Indikation: Endometrial Cancer, Endometriumkarzinom / Veranstaltung: ESGO / Journal: International Journal of Gynecological Cancer
SMARAGD
2025
Differences in health-related Quality of Life in patients with or without progression on palbociclib therapy. Preliminary results from the Non-Interventional Study PERFORM

Bjelic-Radisic, V; Korell, M; Pfeiler, G; Gabrysiak, T; Petersen, V; Deryal, M; Fietz, T; Radosa, J C; Decker, T; Schöttker, B; Knoblich, J; Rhein, U; Wegenast, A; Glastetter, E; Cordova, M; Zanucco, E; Glasstetter, M; Oppermann, U; Bartsch, R; Lux, M P

Senologie 2025; 22(02): 3 – 4

Poster

Indikation: Breast Cancer, Mammakarzinom / Veranstaltung: Senologie Kongress / Journal: Senologie
PERFORM
2025
Real-world effectiveness of palbociclib + endocrine therapy in tumor histological subgroups of patients with HR+/HER2- Advanced Breast Cancer: Interim Results of the PERFORM study.

R. Bartsch, M. Korell, G. Pfeiler, T. Gabrysiak, V. Petersen, M. Deryal, T.J. Fietz, J.C. Radosa, T. Decker, B. Schöttker, J. Knoblich, U. Rhein, N. Deuerling, M. Glasstetter, K. Gratzke, A. Wegenast, E. Glastetter, S. Sener, J. Dzieran, M.P. Lux.

Annals of Oncology, Volume 36, Supplement 2, 2025, Page S394, ISSN 0923-7534, https://doi.org/10.1016/j.annonc.2025.08.942

Poster

Indikation: Breast Cancer, Mammakarzinom / Veranstaltung: ESMO / Journal: Annals of Oncology
PERFORM
2025